NCT04314622 is a Phase 2 clinical trial of Supaglutide in Diabetes Mellitus, Type 2, sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd..

Who is sponsoring NCT04314622?

NCT04314622 is sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd..

What drugs are being tested in NCT04314622?

Interventions in NCT04314622: Supaglutide, Placebo.

What condition does NCT04314622 study?

NCT04314622 studies Diabetes Mellitus, Type 2.

Is NCT04314622 still recruiting?

NCT04314622 is currently completed. Last updated 17 September 2021.

Last reviewed 2021-09-17 · How we verify

NCT04314622

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Supaglutide in Chinese Type 2 Diabetes Patients

Completed Phase 2 Last updated 17 September 2021

What this trial tests

Phase 2 trial testing Supaglutide in Diabetes Mellitus, Type 2 in 40 participants. Completed in 16 March 2021.

Timeline

14 April 2020

Primary endpoint
25 October 2020

16 March 2021

Quick facts

Lead sponsor	Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	14 April 2020
Primary completion	25 October 2020
Estimated completion	16 March 2021
Sites	1 location across China

Drugs / interventions tested

Supaglutide
Placebo

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study on the safety, efficacy, pharmacokinetics and pharmacodynamics of Supaglutide dosing weekly and bi-weekly in patients with type 2 diabetes mellitus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes.
Lou YR, Xu YL, Xiong Y, Deng C, et al · · 2025 · cited 10× · PMID 39961992 · DOI 10.1007/s40262-025-01475-7

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. trials

Trials by the same sponsor.

NCT07518121 — A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil · Phase 1 · not yet recruiting
NCT07114419 — The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE） · Phase 2 · recruiting
NCT06900075 — Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients · Phase 3 · not yet recruiting
NCT06921486 — The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) · Phase 2, PHASE3 · active not recruiting
NCT06849843 — A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients. · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04314622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Last refreshed: 17 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04314622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing